$CC

Cowan Alister purchased $203K of CC

Cowan Alister purchased 13,000 shares of Chemours Co (CC) at $15.62 ($0.20M total) on 2026-08-07.

Original reporting
SEC EDGAR · Cowan Alister
Published Aug 11, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CC
Neutral
low confidence
Mentioned
$CC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CCNeutralLow
01

Why it matters

The disclosed fact is an open-market purchase by a director, with no 10b5-1 plan and a specific trade size and price.

02

Market read

Traders may note the insider buy as a mild sentiment input, but there is no new operational or financial information.

03

What to watch

The article does not state whether the purchase was part of a broader pattern, nor does it provide context like prior holdings changes beyond the post-transaction total.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-11 after-hours; transaction dated 2026-08-07

Background

The article is an SEC Form 4 insider transaction disclosure for Chemours Co (CC).

Company-level read

Ticker impact

$CCNeutralLow confidence
Context

Chemours director Alister Cowan bought 13,000 shares of CC on 2026-08-07 at $15.62, totaling $203,060, per Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan and no accompanying company-specific news (guidance, contracts, litigation, or operational updates).

Market effects

No sector-level implications disclosed; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider buys can be discretionary or tax/portfolio-driven and may not reflect near-term business improvement.

Key entities

  • Chemours Co

    Subject of the Form 4 insider transaction disclosure.

  • Cowan Alister

    Director who purchased 13,000 shares of CC for $203,060.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CCHigh

Why is Chemours stock sliding today?

Chemours (CC) stock fell 2.3% in pre-market trading after Mizuho downgraded it to Neutral and cut its price target to $15. RBC also downgraded it to Sector Perform, reducing its target to $14. Both analysts cited concerns over slower earnings growth and weak demand in key markets. The stock has lost over 40% in six months, trading near its 52-week low.

$CCMed

Mizuho downgrades Chemours stock rating on refrigerants delay

Mizuho downgraded Chemours (NYSE:CC) to Neutral from Outperform, lowering its price target to $15 from $18. The downgrade reflects slower-than-expected earnings growth from new refrigerants and concerns about titanium dioxide pigment market stability. Chemours' stock is down over 41% in the past six months, trading at $13.20. The company reported mixed Q2 2026 results, missing earnings and revenue estimates, and settled PFAS-related claims with North Carolina.

$CCHigh

Chemours falls as RBC downgrades stock on persistent TiO2 weakness

Chemours Co (CC) shares dropped 2.5% premarket after RBC downgraded it to Sector Perform, citing weak TiO2 demand and reduced growth expectations. RBC cut its price target to $14 from $22 and lowered EBITDA estimates for Q3 and FY26-FY27, citing macro pressures and project delays. The analyst sees limited near-term upside and a fully valued stock at current levels.

$CCMedAI 8/10

Corporations Are Dodging Accountability for PFAS Contamination Around the Globe

Chemours, a chemical company, has been linked to PFAS contamination in the Cape Fear River, North Carolina, affecting drinking water and health. The state reached a $590M settlement with Chemours for damages. PFAS contamination has also been reported near Chemours' facilities worldwide, raising concerns about global environmental and health impacts. Chemours inherited cleanup liabilities from its former parent company, DuPont, after a 2015 spin-off.